Review on Preclinical and Clinical Evidence of Food (Beverages, Fruits and Vegetables) and Drug Interactions: Mechanism and Safety

Author(s): Yogesh C. Yadav*, Kamla Pathak, Devender Pathak

Journal Name: Current Drug Therapy

Volume 15 , Issue 1 , 2020

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Background: The therapeutic potency and efficacy of drugs can be affected by a patient’s dietary habit. The food composition and their nutritional value interact with drugs that lead to alteration of the therapeutic response of drugs in patients.

Objective: This present review is an attempt to illustrate clinical reports of food-drug interaction. Further, it also highlights specific interaction mechanism(s) and the safety thereof.

Methods: Through the search engine “Scopus”; literature on recent advances in food and drug interactions includes almost all therapeutic categories such as antimicrobials, antiviral, antifungal, antihistamines, anticoagulants, non-steroidal anti-inflammatory drugs, and drugs acting on the central nervous system and cardiovascular system.

Results: Preclinical and clinical studies that have been conducted by various researchers affirm significant drug-food interactions across the various therapeutic categories of drugs. Preclinical studies have documented the effects of food, milk products, alcohols, fruit and vegetables on the drug absorption, metabolizing enzymes and drug transporters. The clinical studies on fruits/vegetables and drugs interactions report significant alteration in therapeutic response.

Conclusion: Based on the preclinical and clinical reports, it can be concluded that the interaction of food with drug(s) significantly alters their therapeutic potential. The inputs from clinical practitioners to elucidate potential risk of food-drug interaction need to be intensified in order to prevent adverse clinical consequences.

Keywords: Preclinical reports, clinical study, food, drugs, interaction, therapeutic.

[1]
Bobroff BL, Lentz A, Turner ER. Food/drug and drug/nutrient interactions: what you should know about your medications. Univ Florida IFAS Extens 2009; FCS8092: 1-10.
[2]
Bushra R, Aslam N, Khan AY. Food-drug interactions. Oman Med J 2011; 26(2): 77-83.
[http://dx.doi.org/10.5001/omj.2011.21] [PMID: 22043389]
[3]
Boullata JI, Hudson LM. Drug-nutrient interactions: A broad view with implications for practice. J Acad Nutr Diet 2012; 112(4): 506-17.
[http://dx.doi.org/10.1016/j.jada.2011.09.002] [PMID: 22717215]
[4]
Venkateswarulu. 2nd ed. Biopharmaceutics and Pharmacokinetics, Pharma Med Pess 2014; pp. 72-3.
[5]
Braun L. An introduction to: drug-nutrient interactions
[6]
Chan LN. Drug-nutrient interaction in clinical nutrition. Curr Opin Clin Nutr Metab Care 2002; 5(3): 327-32.
[http://dx.doi.org/10.1097/00075197-200205000-00014] [PMID: 11953660]
[7]
Boboof BL, Lentz A, Tumar ER. Food drug interactions and role of Pharmacist. Asian J Pham Clin Res 2009; 2: 1-10.
[8]
Chan LN. Drug-Nutrient Interactions Modern Nutrition in Health and Disease. Baltimore: Lippincott Williams & Wilkins 2006; pp. 1540-53.
[9]
Adams AJ, Clark DR, Delander GE, Nuffer W, Smith M, Ives TJ. Opportunities and responsibilities for the academy in the medical home. Am J Pharm Educ 2013; 77(7): 137.
[http://dx.doi.org/10.5688/ajpe777137] [PMID: 24052643]
[10]
Tipathi KD. Essential of medical pharmacology. Jaypee Bothers Medical Publishers (P). Ltd 2015; 07: 22-36.
[11]
Singh BN, Malhotra BK. Effects of food on the clinical pharmacokinetics of anticancer agents: Underlying mechanisms and implications for oral chemotherapy. Clin Pharmacokinet 2004; 43(15): 1127-56.
[http://dx.doi.org/10.2165/00003088-200443150-00005] [PMID: 15568891]
[12]
Beermann B, Groschinsky-Grind M. Gastrointestinal absorption of hydrochlorothiazide enhanced by concomitant intake of food. Eur J Clin Pharmacol 1978; 13(2): 125-8.
[http://dx.doi.org/10.1007/BF00609756] [PMID: 658108]
[13]
Janus K, Grochowina B, Antoszek J, Suszycki S, Muszczynski Z. The effect of food or water deprivation on paracetamol pharmacokinetics in calves. J Vet Pharmacol Ther 2003; 26(4): 291-6.
[http://dx.doi.org/10.1046/j.1365-2885.2003.00482.x] [PMID: 12887612]
[14]
Choi JH, Ko CM. Review on food and drug interaction. J Lifestyle Med 2017; 7(1): 1-9.
[http://dx.doi.org/10.15280/jlm.2017.7.1.1] [PMID: 28261555]
[15]
Fish DN. Fluoroquinolone adverse effects and drug interactions. Pharmacotherapy 2001; 21(10 Pt 2): 253S-72S.
[http://dx.doi.org/10.1592/phco.21.16.253S.33993] [PMID: 11642691]
[16]
Schmidt LE, Dalhoff K. Food-drug interactions. Drugs 2002; 62(10): 1481-502.
[http://dx.doi.org/10.2165/00003495-200262100-00005] [PMID: 12093316]
[17]
Le Tiec C, Barrail A, Goujard C, Taburet AM. Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir. Clin Pharmacokinet 2005; 44(10): 1035-50.
[http://dx.doi.org/10.2165/00003088-200544100-00003] [PMID: 16176117]
[18]
Moore RA, Derry S, Wiffen PJ, Straube S. Effects of food on pharmacokinetics of immediate release oral formulations of aspirin, dipyrone, paracetamol and NSAIDs - a systematic review. Br J Clin Pharmacol 2015; 80(3): 381-8.
[http://dx.doi.org/10.1111/bcp.12628] [PMID: 25784216]
[19]
Chan LN. Drug-nutrient interactions. JPEN J Parenter Enteral Nutr 2013; 37(4): 450-9.
[http://dx.doi.org/10.1177/0148607113488799] [PMID: 23674575]
[20]
Srinivas NR, Ramesh M. Digoxin - a therapeutic agent and mechanistic probe: Review of liquid chromatographic mass spectrometric methods and recent nuances in the clinical pharmacology attributes of digoxin. Bioanalysis 2009; 1(1): 97-113.
[http://dx.doi.org/10.4155/bio.09.14] [PMID: 21083191]
[21]
González Canga A, Fernández Martínez N, Sahagún Prieto AM, et al. Dietary fiber and its interaction with drugs. Nutr Hosp 2010; 25(4): 535-9.
[PMID: 20694287]
[22]
Péter S, Navis G, de Borst MH, et al. Public health relevance of drug-nutrition interactions. Eur J Nutr 2017; 56(Suppl. 2): 23-36.
[http://dx.doi.org/10.1007/s00394-017-1510-3] [PMID: 28748481]
[23]
Nyholm D, Odin P, Johansson A, et al. Pharmacokinetics of levodopa, carbidopa, and 3-O-methyldopa following 16-hour jejunal infusion of levodopa-carbidopa intestinal gel in advanced Parkinson’s disease patients. AAPS J 2013; 15(2): 316-23.
[http://dx.doi.org/10.1208/s12248-012-9439-1] [PMID: 23229334]
[24]
Ko JH, Lerner RP, Eidelberg D. Effects of levodopa on regional cerebral metabolism and blood flow. Mov Disord 2015; 30(1): 54-63.
[http://dx.doi.org/10.1002/mds.26041] [PMID: 25296957]
[25]
Guebila MB, Thiele I. Model-based dietary optimization for late-stage, levodopa-treated, Parkinson’s disease patients. NPJ Syst Biol Appl 2016; 2: 16013.
[http://dx.doi.org/10.1038/npjsba.2016.13] [PMID: 28725472]
[26]
Wang L, Xiong N, Huang J, et al. Protein-restricted diets for ameliorating motor fluctuations in Parkinson’s disease. Front Aging Neurosci 2017; 9: 206.
[http://dx.doi.org/10.3389/fnagi.2017.00206] [PMID: 28701947]
[27]
Chen HO, Reilly E, McCullough ML, et al. Dairy products and risk of Parkinson’s disease. Am J Epidemiol 2007; 165(9): 998-1006.
[http://dx.doi.org/10.1093/aje/kwk089] [PMID: 17272289]
[28]
Hyman Rapaport M. Translating the evidence on atypical depression into clinical practice. J Clin Psychiatry 2007; 68(Suppl. 3): 31-6.
[PMID: 17348765]
[29]
Choi JH, Ko CM. Food and drug interactions. J Lifestyle Med 2017; 7(1): 1-9.
[http://dx.doi.org/10.15280/jlm.2017.7.1.1] [PMID: 28261555]
[30]
Cascorbi I. Drug interactions-principles, examples and clinical consequences. Dtsch Arztebl Int 2012; 109(33-34): 546-55.
[PMID: 23152742]
[31]
Fiaz T, Fatima N, Zaidi SZA, Abbas T, Kazimi MR. Investigation of iron complex formation of anti-hypertensive drug: Methyldopa. Am J Anal Chem 2015; 6: 551-8.
[http://dx.doi.org/10.4236/ajac.2015.66053]
[32]
Campbell NR, Hasinoff BB. Iron supplements: A common cause of drug interactions. Br J Clin Pharmacol 1991; 31(3): 251-5.
[http://dx.doi.org/10.1111/j.1365-2125.1991.tb05525.x] [PMID: 2054263]
[33]
Heelon MW, White M. Disulfiram-cotrimoxazole reaction. Pharmacotherapy 1998; 18(4): 869-70.
[PMID: 9692665]
[34]
Debnath S, Tejovathi R, Basu N, Harish TK. An overview on food and drug interactions. Pharm Times 2017; 49(4): 9-15.
[35]
Islam S, Majeed IM. Nadeem Alvi. Drug food interactions in various therapies. Indo American J Pharm Res 2015; 5(04): 1570-80.
[36]
Rodriguez de la Torre B, Dreher J, Malevany I, et al. Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients. Ther Drug Monit 2001; 23(4): 435-40.
[http://dx.doi.org/10.1097/00007691-200108000-00019] [PMID: 11477329]
[37]
Bailey DG, Malcolm J, Arnold O, Spence JD. Grapefruit juice-drug interactions. Br J Clin Pharmacol 1998; 46(2): 101-10.
[http://dx.doi.org/10.1046/j.1365-2125.1998.00764.x] [PMID: 9723817]
[38]
Parker JC. Troglitazone: the discovery and development of a novel therapy for the treatment of Type 2 diabetes mellitus. Adv Drug Deliv Rev 2002; 54(9): 1173-97.
[http://dx.doi.org/10.1016/S0169-409X(02)00093-5] [PMID: 12393300]
[39]
Young MA, Lettis S, Eastmond R. Improvement in the gastrointestinal absorption of troglitazone when taken with, or shortly after, food. Br J Clin Pharmacol 1998; 45(1): 31-5.
[http://dx.doi.org/10.1046/j.1365-2125.1998.00653.x] [PMID: 9489591]
[40]
Finberg JP, Gillman K. Selective inhibitors of monoamine oxidase type B and the “cheese effect”. Int Rev Neurobiol 2011; 100: 169-90.
[http://dx.doi.org/10.1016/B978-0-12-386467-3.00009-1] [PMID: 21971008]
[41]
Bennet PN, Brown MJ. Clinical pharmacology. 9th ed. New York: Churchill Livingstone publishers 2003; pp. 128-33.
[42]
McCrindle JL, Li Kam Wa TC, Barron W, Prescott LF. Effect of food on the absorption of furosemide and bumetanide in man. Br J Clin Pharmacol 1996; 42(6): 743-6-53.
[43]
Paintaud G, Alván G, Eckernäs SA, Wakelkamp M, Grahnén A. The influence of food intake on the effect of two controlled release formulations of furosemide. Biopharm Drug Dispos 1995; 16(3): 221-32.
[http://dx.doi.org/10.1002/bdd.2510160307] [PMID: 7787134]
[44]
Domenic A. Sica, drug absorption in the management of congestive heart failure: Loop diuretics. Pharmacotherapy in CHF 2003; pp. 287-2.
[45]
Hammarlund MM, Paalzow LK, Odlind B. Pharmacokinetics of furosemide in man after intravenous and oral administration. Application of moment analysis. Eur J Clin Pharmacol 1984; 26(2): 197-207.
[http://dx.doi.org/10.1007/BF00630286] [PMID: 6723758]
[46]
Fülöp T, Zsom L, Rodríguez B, et al. Clinical utility of potassium-sparing diuretics to maintain normal serum potassium in peritoneal dialysis patients. Perit Dial Int 2017; 37(1): 63-9.
[http://dx.doi.org/10.3747/pdi.2016.00022] [PMID: 27282853]
[47]
Johnson MA. Influence of vitamin K on anticoagulant therapy depends on vitamin K status and the source and chemical forms of vitamin K. Nutr Rev 2005; 63(3): 91-7.
[http://dx.doi.org/10.1111/j.1753-4887.2005.tb00126.x] [PMID: 15825811]
[48]
Tsukamoto Y, Ichise H, Kakuda H, Yamaguchi M. Intake of fermented soybean (natto) increases circulating vitamin K2 (menaquinone-7) and gamma-carboxylated osteocalcin concentration in normal individuals. J Bone Miner Metab 2000; 18(4): 216-22.
[http://dx.doi.org/10.1007/s007740070023] [PMID: 10874601]
[49]
Sanyal PK, Rawte D, Kerketta AE, et al. Diet-induced modulation of pharmacokinetics of albendazole in Sahiwal cattle. J Helminthol 2016; 90(5): 555-60.
[http://dx.doi.org/10.1017/S0022149X15000735] [PMID: 26306773]
[50]
Dixon R, Pozniak AL, Watt HM, Rolan P, Posner J. Single-dose and steady-state pharmacokinetics of a novel microfluidized suspension of atovaquone in human immunodeficiency virus-seropositive patients. Antimicrob Agents Chemother 1996; 40(3): 556-60.
[http://dx.doi.org/10.1128/AAC.40.3.556] [PMID: 8851570]
[51]
Falloon J, Sargent S, Piscitelli SC, et al. Atovaquonesuspension in HIV-infected volunteers: Pharmacokinetics, pharmacodynamics, and TMP-SMX interaction study. Pharmacotherapy 1999; 19(9): 1050-6-6.
[52]
Freeman CD, Klutman NE, Lamp KC, Dall LH, Strayer AH. Relative bioavailability of atovaquone suspension when administered with an enteral nutrition supplement. Ann Pharmacother 1998; 32(10): 1004-7-7.
[http://dx.doi.org/10.1345/aph.17464]
[53]
Rolan PE, Mercer AJ, Weatherley BC, et al. Examination of some factors responsible for a food-induced increase in absorption of atovaquone. Br J Clin Pharmacol 1994; 37(1): 13-20.
[http://dx.doi.org/10.1111/j.1365-2125.1994.tb04232.x] [PMID: 8148213]
[54]
Nachipo P, Hermann D, Quinnan G, Gordon MA, Van Voorhis WC, Iroh Tam PY. Evaluating the safety, tolerability, pharmacokinetics and efficacy of clofazimine in cryptosporidiosis (CRYPTOFAZ): Study protocol for a randomized controlled trial. Trials 2018; 19(1): 456.
[55]
Khalafalla N, Elgholmy ZA, Khalil SA. Influence of high fat diet on GI absorption of griseofulvin tablets in man. Pharmazie 1981; 36(10): 692-3.
[PMID: 7312923]
[56]
Batchelor HK. Influence of food on paediatric gastrointestinal drug absorption following oral administration: A review. Children (Basel) 2015; 2(2): 244-71.
[http://dx.doi.org/10.3390/children2020244]
[57]
Zhi J, Rakhit A, Patel IH. Effects of dietary fat on drug absorption. Clin Pharmacol Ther 1995; 58(5): 487-91.
[http://dx.doi.org/10.1016/0009-9236(95)90167-1] [PMID: 7586941]
[58]
Barone JA, Koh JG, Bierman RH, et al. Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers. Antimicrob Agents Chemother 1993; 37(4): 778-84.
[http://dx.doi.org/10.1128/AAC.37.4.778]
[59]
Van Peer A, Woestenborghs R, Heykants J, Gasparini R. The effects of food and dose on the oral systemic availability of itraconazole in healthy subjects. Eur J Clin Pharmacol 1989; 36(4): 423-6.
[60]
Mouton JW, van Peer A, de Beule K, Van Vliet A, Donnelly JP, Soons PA. Pharmacokinetics of itraconazole and hydroxyitraconazole in healthy subjects after single and multiple doses of a novel formulation. Antimicrob Agents Chemother 2006; 50(12): 4096-102.
[http://dx.doi.org/10.1128/AAC.00630-06] [PMID: 16982783]
[61]
Zimmermann T, Yeates RA, Albrecht M, Laufen H, Wildfeuer A. Influence of concomitant food intake on the gastrointestinal absorption of fluconazole and itraconazole in Japanese subjects. Int J Clin Pharmacol Res 1994; 14(3): 87-93.
[62]
Zimmermann T, Yeates RA, Laufen H, Pfaff G, Wildfeuer A. Influence of concomitant food intake on the oral absorption of two triazole antifungal agents, itraconazole and fluconazole. Eur J Clin Pharmacol 1994; 46(2): 147-50.
[http://dx.doi.org/10.1007/BF00199879] [PMID: 8039534]
[63]
Richter WO, Jacob BG, Schwandt P. Interaction between fibre and lovastatin. Lancet 1991; 338(8768): 706-90.
[http://dx.doi.org/10.1016/0140-6736(91)91291-2] [PMID: 1679514]
[64]
Rogers JD, Zhao J, Liu L, et al. Grapefruit juice has minimal effects on plasma concentrations of lovastatin-derived 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Clin Pharmacol Ther 1999; 66(4): 358-66.
[http://dx.doi.org/10.1053/cp.1999.v66.a101208] [PMID: 10546919]
[65]
Karim A, Rozek LF, Smith ME, Kowalski KG. Effects of food and antacid on oral absorption of misoprostol, asynthetic prostaglandin E1 analog. J Clin Pharmacol 1989; 29(5): 439-43.
[66]
Rutgeerts P, Vantrappen G, Hiele M. Postprandial administration of prostaglandin (misoprostol) produces less adverse effects on intestinal transit than its preprandial administration. Gastroenterology 1988; 94(5 Pt 2): A391.
[67]
Swanson BN, Vlasses PH, Ferguson RK, et al. Influence of food on the bioavailability of enalapril. J Pharm Sci 1984; 73(11): 1655-7.
[http://dx.doi.org/10.1002/jps.2600731146] [PMID: 6097665]
[68]
Mojaverian P, Rocci ML Jr, Vlasses PH, Hoholick C, Clementi RA, Ferguson RK. Effect of food on the bioavailability of lisinopril, a nonsulfhydryl angiotensin-converting enzyme inhibitor. J Pharm Sci 1986; 75(4): 395-7.
[http://dx.doi.org/10.1002/jps.2600750416] [PMID: 3014110]
[69]
Chung M, Calcagni A, Glue P, Bramson C. Effect of food on the bioavailability of amlodipine besylate/atorvastatin calcium combination tablet. J Clin Pharmacol 2006; 46(10): 1212-6.
[http://dx.doi.org/10.1177/0091270006291097] [PMID: 16988211]
[70]
Whitfield LR, Stern RH, Sedman AJ, Abel R, Gibson DM. Effect of food on the pharmacodynamics and pharmacokinetics of atorvastatin, an inhibitor of HMG-CoA reductase. Eur J Drug Metab Pharmacokinet 2000; 25(2): 97-101.
[http://dx.doi.org/10.1007/BF03190074] [PMID: 11112089]
[71]
Dujovne CA, Davidson MH. Fluvastatin administration at bedtime versus with the evening meal: a multicenter comparison of bioavailability, safety, and efficacy. Am J Med 1994; 96(6A): 37S-40S.
[http://dx.doi.org/10.1016/0002-9343(94)90230-5] [PMID: 8017465]
[72]
Woo E, Greenblatt DJ. Effect of food on enteral absorption of quinidine. Clin Pharmacol Ther 1980; 27(2): 188-93.
[http://dx.doi.org/10.1038/clpt.1980.29] [PMID: 7353338]
[73]
Kenyon CJ, Brown F, McClelland GRR, Wilding IR. The use of pharmacoscintigraphy to elucidate food effects observed with a novel protease inhibitor (saquinavir). Pharm Res 1998; 15(3): 417-22.
[http://dx.doi.org/10.1023/A:1011972230829] [PMID: 9563071]
[74]
Kupferschmidt HH, Fattinger KE, Ha HR, Follath F, Krähenbühl S. Grapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in man. Br J Clin Pharmacol 1998; 45(4): 355-9.
[http://dx.doi.org/10.1046/j.1365-2125.1998.t01-1-00687.x] [PMID: 9578182]
[75]
McNamara PJ, Jewell RC, Jensen BK, Brindley CJ. Food increases the bioavailability of acitretin. J Clin Pharmacol 1988; 28(11): 1051-5.
[http://dx.doi.org/10.1002/j.1552-4604.1988.tb03129.x] [PMID: 2977392]
[76]
Eshelman FN, Spyker DA. Pharmacokinetics of amoxicillin and ampicillin: Crossover study of the effect of food. Antimicrob Agents Chemother 1978; 14(4): 539-43.
[http://dx.doi.org/10.1128/AAC.14.4.539] [PMID: 363052]
[77]
Neu HC. Antimicrobial activity and human pharmacology of amoxicillin. J Infect Dis 1974; 129(0): S123-31.
[http://dx.doi.org/10.1093/infdis/129.Supplement_2.S123] [PMID: 4601187]
[78]
Neuvonen PJ, Elonen E, Pentikäinen PJ. Comparative effect of food on absorption of ampicillin and pivampicillin. J Int Med Res 1977; 5(1): 71-6.
[http://dx.doi.org/10.1177/030006057700500113] [PMID: 838114]
[79]
Welling PG, Huang H, Koch PA, Craig WA, Madsen PO. Bioavailability of ampicillin and amoxicillin in fasted and nonfasted subjects. J Pharm Sci 1977; 66(4): 549-52.
[http://dx.doi.org/10.1002/jps.2600660423] [PMID: 323461]
[80]
Hopkins S. Clinical toleration and safety of azithromycin. Am J Med 1991; 91(3A): 40S-5S.
[http://dx.doi.org/10.1016/0002-9343(91)90401-I] [PMID: 1656742]
[81]
Hartman NR, Yarchoan R, Pluda JM, et al. Pharmacokinetics of 2′,3′-dideoxyadenosine and 2′,3′-dideoxyinosine in patients with severe human immunodeficiency virus infection. Clin Pharmacol Ther 1990; 47(5): 647-54.
[http://dx.doi.org/10.1038/clpt.1990.86] [PMID: 2111751]
[82]
Knupp CA, Milbrath R, Barbhaiya RH. Effect of time of food administration on the bioavailability of didanosine from a chewable tablet formulation. J Clin Pharmacol 1993; 33(6): 568-73.
[http://dx.doi.org/10.1002/j.1552-4604.1993.tb04705.x] [PMID: 8366182]
[83]
Rutland J, Berend N, Marlin GE. The influence of food on the bioavailability of new formulations of erythromycin stearate and base. Br J Clin Pharmacol 1979; 8(4): 343-7.
[http://dx.doi.org/10.1111/j.1365-2125.1979.tb04716.x] [PMID: 508509]
[84]
Digranes A, Josefsson K, Schreiner A. Influence of food on the absorption of erythromycin from enteric-coated pellets and stearate tablets. Curr Ther Res Clin Exp 1984; 35(3): 313-20.
[85]
Mäntylä R, Ailio A, Allonen H, Kanto J. Bioavailability and effect of food on the gastrointestinal absorption of two erythromycin derivatives. Ann Clin Res 1978; 10(5): 258-62.
[PMID: 367255]
[86]
Randinitis EJ, Sedman AJ, Welling PG, Kinkel AW. Effect of a high-fat meal on the bioavailability of a polymer-coated erythromycin particle tablet formulation. J Clin Pharmacol 1989; 29(1): 79-84.
[http://dx.doi.org/10.1002/j.1552-4604.1989.tb03241.x] [PMID: 2708552]
[87]
Milton KA, Edwards G, Ward SA, Orme ML, Breckenridge AM. Pharmacokinetics of halofantrine in man: Effects of food and dose size. Br J Clin Pharmacol 1989; 28(1): 71-7.
[http://dx.doi.org/10.1111/j.1365-2125.1989.tb03507.x] [PMID: 2775616]
[88]
Yeh KC, Deutsch PJ, Haddix H, et al. Single-dose pharmacokinetics of indinavir and the effect of food. Antimicrob Agents Chemother 1998; 42(2): 332-8.
[http://dx.doi.org/10.1128/AAC.42.5.1308] [PMID: 9527781]
[89]
Joshi MV, Saraf YS, Kshirsagar NA, Acharya VN. Food reduces isoniazid bioavailability in normal volunteers. J Assoc Physicians India 1991; 39(6): 470-1.
[PMID: 1938852]
[90]
Männisto P, Mäntylä R, Klinge E, Nykänen S, Koponen A, Lamminsivu U. Influence of various diets on the bioavailability of isoniazid. J Antimicrob Chemother 1982; 10(5): 427-34.
[http://dx.doi.org/10.1093/jac/10.5.427] [PMID: 7174567]
[91]
Lin HC, Yu MC, Liu HJ, Bai KJ. Impact of food intake on the pharmacokinetics of first-line antituberculosis drugs in Taiwanese tuberculosis patients. J Formos Med Assoc 2014; 113(5): 291-7.
[http://dx.doi.org/10.1016/j.jfma.2014.01.015] [PMID: 24594059]
[92]
Peloquin CA, Namdar R, Dodge AA, Nix DE. Pharmacokinetics of isoniazid under fasting conditions, with food, and with antacids. Int J Tuberc Lung Dis 1999; 3(8): 703-10.
[PMID: 10460103]
[93]
Zent C, Smith P. Study of the effect of concomitant food on the bioavailability of rifampicin, isoniazid and pyrazinamide. Tuber Lung Dis 1995; 76(2): 109-13.
[http://dx.doi.org/10.1016/0962-8479(95)90551-0] [PMID: 7780091]
[94]
Van Peer AP, Heykants JJ, Woestenborghs RJ, Van Rooy P, De Beule KL, Cauwenbergh GF. Effect of food on the pharmacokinetics of a new hydroxyl propyl-beta-cyclodextrin formulation of itraconazole. Pharmacotherapy 1996; 16(3): 424-8.
[PMID: 8726601]
[95]
Astarloa R, Mena MA, Sánchez V, de la Vega L, de Yébenes JG. Clinical and pharmacokinetic effects of a diet rich in insoluble fiber on Parkinson disease. Clin Neuropharmacol 1992; 15(5): 375-80.
[http://dx.doi.org/10.1097/00002826-199210000-00004] [PMID: 1330307]
[96]
Baruzzi A, Contin M, Riva R, et al. Influence of meal ingestion time on pharmacokinetics of orally administered levodopa in parkinsonian patients. Clin Neuropharmacol 1987; 10(6): 527-37.
[http://dx.doi.org/10.1097/00002826-198712000-00004] [PMID: 3427559]
[97]
Contin M, Riva R, Martinelli P, Albani F, Baruzzi A. Effect of meal timing on the kinetic-dynamic profile of levodopa/carbidopa controlled release [corrected] in parkinsonian patients. Eur J Clin Pharmacol 1998; 54(4): 303-8.
[http://dx.doi.org/10.1007/s002280050464] [PMID: 9696954]
[98]
Nutt JG, Woodward WR, Hammerstad JP, Carter JH, Anderson JL. The “on-off” phenomenon in Parkinson’s disease. Relation to levodopa absorption and transport. N Engl J Med 1984; 310(8): 483-8.
[http://dx.doi.org/10.1056/NEJM198402233100802] [PMID: 6694694]
[99]
Malcolm SL, Allen JG, Bird H, et al. Single-dose pharmacokinetics of Madopar HBS in patients and effect of food and antacid on the absorption of Madopar HBS in volunteers. Eur Neurol 1987; 27(Suppl. 1): 28-35.
[http://dx.doi.org/10.1159/000116172] [PMID: 3428307]
[100]
Dupuis LL, Koren G, Silverman ED, Laxer RM. Influence of food on the bioavailability of oral methotrexate in children. J Rheumatol 1995; 22(8): 1570-3.
[PMID: 7473485]
[101]
Madanat F, Awidi A, Shaheen O, Othman S, Al-Turk W. Effects of food and gender on the pharmacokinetics of methotrexate in children. Res Commun Chem Pathol Pharmacol 1987; 55(2): 279-82.
[PMID: 3823614]
[102]
Zhang C, Zhai S, Yang L, Wu H, Zhang J, Ke X. Population pharmacokinetic study of methotrexate in children with acute lymphoblastic leukemia. Int J Clin Pharmacol Ther 2010; 48(1): 11-21.
[http://dx.doi.org/10.5414/CPP48011] [PMID: 20040335]
[103]
Burton NK, Barnett MJ, Aherne GW, Evans J, Douglas I, Lister TA. The effect of food on the oral administration of 6-mercaptopurine. Cancer Chemother Pharmacol 1986; 18(1): 90-1.
[http://dx.doi.org/10.1007/BF00253074] [PMID: 3757164]
[104]
Lönnerholm G, Kreuger A, Lindström B, Myrdal U. Oral mercaptopurine in childhood leukemia: Influence of food intake on bioavailability. Pediatr Hematol Oncol 1989; 6(2): 105-12.
[http://dx.doi.org/10.3109/08880018909034276] [PMID: 2702064]
[105]
Riccardi R, Balis FM, Ferrara P, Lasorella A, Poplack DG, Mastrangelo R. Influence of food intake on bioavailability of oral 6-mercaptopurine in children with acute lymphoblastic leukemia. Pediatr Hematol Oncol 1986; 3(4): 319-24.
[http://dx.doi.org/10.3109/08880018609031233] [PMID: 3153245]
[106]
Pyysalo M, Helminen M, Antalainen AK, Sándor GK, Wolff J. Antibiotic prophylaxis patterns of Finnish dentists performing dental implant surgery. Acta Odontol Scand 2014; 72(8): 806-10.
[http://dx.doi.org/10.3109/00016357.2014.913194] [PMID: 24791607]
[107]
Finkel Y, Bolme P, Eriksson M. The effect of food on the oral absorption of penicillin V preparations in children. Acta Pharmacol Toxicol (Copenh) 1981; 49(4): 301-4.
[http://dx.doi.org/10.1111/j.1600-0773.1981.tb00910.x] [PMID: 6805255]
[108]
Barza M, Weinstein L. Pharmacokinetics of the penicillins in man. Clin Pharmacokinet 1976; 1(4): 297-308.
[http://dx.doi.org/10.2165/00003088-197601040-00004] [PMID: 797501]
[109]
Lecocq B, Funck-Brentano C, Lecocq V, et al. Influence of food on the pharmacokinetics of perindopril and the time course of angiotensin-converting enzyme inhibition in serum. Clin Pharmacol Ther 1990; 47(3): 397-402.
[http://dx.doi.org/10.1038/clpt.1990.45] [PMID: 2311339]
[110]
Zwolska Z, Augustynowicz-Kopeć E, Niemirowska-Mikulska H. The pharmacokinetic factors and bioavailability of rifampicin, isoniazid and pyrazinamid fixed in one dose capsule. Acta Pol Pharm 2002; 59(6): 448-52.
[PMID: 12669769]
[111]
Saktiawati AM, Sturkenboom MG, Stienstra Y, et al. Impact of food on the pharmacokinetics of first-line anti-TB drugs in treatment-naive TB patients: a randomized cross-over trial. J Antimicrob Chemother 2016; 71(3): 703-10.
[http://dx.doi.org/10.1093/jac/dkv394] [PMID: 26661397]
[112]
Shimomura H, Nogami R, Shigeno A, Shimada S, Aoyama T. Influence of food on rifampicin pharmacokinetics in rats. Biol Pharm Bull 2016; 39(1): 49-53.
[http://dx.doi.org/10.1248/bpb.b15-00445] [PMID: 26725427]
[113]
Peloquin CA, Namdar R, Singleton MD, Nix DE. Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids. Chest 1999; 115(1): 12-8.
[http://dx.doi.org/10.1378/chest.115.1.12] [PMID: 9925057]
[114]
Verbist L, Gyselen A. Antituberculous activity of rifampin in vitro and in vivo and the concentrations attained in human blood. Am Rev Respir Dis 1968; 98(6): 923-32.
[PMID: 4972215]
[115]
Booth SL, Charnley JM, Sadowski JA, Saltzman E, Bovill EG, Cushman M. Dietary vitamin K1 and stability of oral anticoagulation: Proposal of a diet with constant vitamin K1 content. Thromb Haemost 1997; 77(3): 504-9.
[http://dx.doi.org/10.1055/s-0038-1655997] [PMID: 9066002]
[116]
Neuvonen PJ, Kivistö KT, Lehto P. Interference of dairy products with the absorption of ciprofloxacin. Clin Pharmacol Ther 1991; 50(5 Pt 1): 498-502.
[http://dx.doi.org/10.1038/clpt.1991.174] [PMID: 1934862]
[117]
Awadzi K, Addy ET, Opoku NO, Plenge-Bönig A, Büttner DW. The chemotherapy of onchocerciasis XX: Ivermectin in combination with albendazole. Trop Med Parasitol 1995; 46(4): 213-20.
[PMID: 8826100]
[118]
Cook GJ, Blake GM, Fogelman I. The time of day that etidronate is ingested does not influence its therapeutic effect in osteoporosis. Scand J Rheumatol 2000; 29(1): 62-4.
[119]
Meijer LA, Ceyssens KG, de Grève BI, de Bruijn W. Pharmacokinetics and bioavailability of doxycycline hyclate after oral administration in calves. Vet Q 1993; 15: 1-5.
[120]
Minami R, Inotsume N, Nakano M, Sudo Y, Higashi A, Matsuda I. Effect of milk on absorption of norfloxacin in healthy volunteers. J Clin Pharmacol 1993; 33(12): 1238-40.
[http://dx.doi.org/10.1002/j.1552-4604.1993.tb03926.x] [PMID: 8126259]
[121]
Ray K, Dorman S, Watson R. Severe hyperkalaemia due to the concomitant use of salt substitutes and ACE inhibitors in hypertension: a potentially life threatening interaction. J Hum Hypertens 1999; 13(10): 717-20.
[http://dx.doi.org/10.1038/sj.jhh.1000890] [PMID: 10516744]
[122]
Bergstrom RF, Kay DR, Harkcom TM, Wagner JG. Penicillamine kinetics in normal subjects. Clin Pharmacol Ther 1981; 30(3): 404-13.
[http://dx.doi.org/10.1038/clpt.1981.180] [PMID: 7273605]
[123]
Osman MA, Patel RB, Schuna A, Sundstrom WR, Welling PG. Reduction in oral penicillamine absorption by food, antacid, and ferrous sulfate. Clin Pharmacol Ther 1983; 33(4): 465-70.
[http://dx.doi.org/10.1038/clpt.1983.63] [PMID: 6831825]
[124]
Schuna A, Osman MA, Patel RB, Welling PG, Sundstrom WR. Influence of food on the bioavailability of penicillamine. J Rheumatol 1983; 10(1): 95-7.
[PMID: 6842493]
[125]
Reardon LC, Macpherson DS. Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors. How much should we worry? Arch Intern Med 1998; 158(1): 26-32.
[http://dx.doi.org/10.1001/archinte.158.1.26] [PMID: 9437375]
[126]
Linda B. Food/drug and drug/nutrient interactions IFAS extension FCS8092. 2009; 1-10.
[127]
Leonard CE, Razzaghi H, Freeman CP, Roy JA, Newcomb CW, Hennessy S. Empiric Potassium supplementation and increased survival in users of loop diuretics. PLoS One 2014; 9(7)e102279
[http://dx.doi.org/10.1371/journal.pone.0102279]
[128]
Batra V, Villgran V. Hyperkalemia from Dietary Supplements. Cureus 2016; 8(11)e859
[http://dx.doi.org/10.7759/cureus.859]
[129]
Mallet L, Schittecatte M. Monoamine oxidase inhibitors and food precautions. A comparison of utilization in Belgian psychiatric education institutes and current findings in the literature. Acta Psychiatr Belg 1996; 96(2): 74-100.
[PMID: 8693949]
[130]
Entzeroth M, Ratty AK. Monoamine oxidase inhibitors-revisiting a therapeutic principle. Open J Depress 2017; 6: 31-68.
[131]
Johnson BA, Seneviratne C. Alcohol-medical drug interactions. Handb Clin Neurol 2014; 125: 543-59.
[http://dx.doi.org/10.1016/B978-0-444-62619-6.00031-8] [PMID: 25307595]
[132]
Harries DP, Teale KF, Sunderland G. Metronidazole and alcohol: Potential problems. Scott Med J 1990; 35(6): 179-80.
[http://dx.doi.org/10.1177/003693309003500608] [PMID: 2077651]
[133]
Kane GC, Wicks SM, Lawal TO, Mahady GB. Drug Interactions with food and beverages. Nutrition Guide for Physicians and Related Healthcare Professionals 2017; pp. 341-9.
[134]
Dart RC. The use and effect of analgesics in patients who regularly drink alcohol. Am J Manag Care 2001; 7(Suppl. 9): S597-601.
[PMID: 11776482]
[135]
Paśko P, Rodacki T, Domagała-Rodacka R, Palimonka K, Marcinkowska M, Owczarek D. Second generation H1 - antihistamines interaction with food and alcohol-A systematic review. Biomed Pharmacother 2017; 93: 27-39.
[http://dx.doi.org/10.1016/j.biopha.2017.06.008] [PMID: 28622592]
[136]
Pinson GM, Beall JW, Kyle JA. A review of warfarin dosing with concurrent acetaminophen therapy. J Pharm Pract 2013; 26(5): 518-21.
[http://dx.doi.org/10.1177/0897190013488802] [PMID: 23736105]
[137]
Havrda DE, Mai T, Chonlahan J. Enhanced antithrombotic effect of warfarin associated with low-dose alcohol consumption. Pharmacotherapy 2005; 25(2): 303-7.
[http://dx.doi.org/10.1592/phco.25.2.303.56955] [PMID: 15767245]
[138]
Kline SS, Mauro VF, Forney RB Jr, Freimer EH, Somani P. Cefotetan-induced disulfiram-type reactions and hypoprothrombinemia. Antimicrob Agents Chemother 1987; 31(9): 1328-31.
[http://dx.doi.org/10.1128/AAC.31.9.1328] [PMID: 3479045]
[139]
Norrby SR. Adverse reactions and interactions with newer cephalosporin and cephamycin antibiotics. Med Toxicol 1986; 1(1): 32-46.
[http://dx.doi.org/10.1007/BF03259826] [PMID: 3537614]
[140]
Tillonen J, Väkeväinen S, Salaspuro V, et al. Metronidazole increases intracolonic but not peripheral blood acetaldehyde in chronic ethanol-treated rats. Alcohol Clin Exp Res 2000; 24(4): 570-5.
[http://dx.doi.org/10.1111/j.1530-0277.2000.tb02026.x] [PMID: 10798595]
[141]
Moore AA, Whiteman EJ, Ward KT. Risks of combined alcohol/medication use in older adults. Am J Geriatr Pharmacother 2007; 5(1): 64-74.
[http://dx.doi.org/10.1016/j.amjopharm.2007.03.006] [PMID: 17608249]
[142]
Burge MR, Zeise TM, Sobhy TA, Rassam AG, Schade DS. Low-dose ethanol predisposes elderly fasted patients with type 2 diabetes to sulfonylurea-induced low blood glucose. Diabetes Care 1999; 22(12): 2037-43.
[http://dx.doi.org/10.2337/diacare.22.12.2037] [PMID: 10587839]
[143]
Hartling SG, Faber OK, Wegmann ML, Wåhlin-Boll E, Melander A. Interaction of ethanol and glipizide in humans. Diabetes Care 1987; 10(6): 683-6.
[http://dx.doi.org/10.2337/diacare.10.6.683] [PMID: 3428047]
[144]
Jolicoeur FB, Rondeau DB, Wayner MJ, Mintz RB, Merkel AD. Barbiturates and alcohol. Biobehav Rev 1977; 1(3): 177-96.
[http://dx.doi.org/10.1016/0147-7552(77)90006-7]
[145]
Linnoila MI. Benzodiazepines and alcohol. J Psychiatr Res 1990; 24(Suppl. 2): 121-7.
[http://dx.doi.org/10.1016/0022-3956(90)90043-P] [PMID: 1980691]
[146]
Gregory M, Weiss MDRA. Methotrexate and Alcohol May Mix Well, to a Degree. Rheumatoid Arthritis 2017.
[147]
Witenko C, Moorman-Li R, Motycka C, et al. Considerations for the appropriate use of skeletal muscle relaxants for the management of acute low back pain. P&T 2014; 39(6): 427-35.
[PMID: 25050056]
[148]
Shin WS, Shin CS, Yeoun PS. The influence of forest therapy camp on depression in alcoholics. Environ Health Prev Med 2012; 17(1): 73-6.
[http://dx.doi.org/10.1007/s12199-011-0215-0] [PMID: 21503628]
[149]
Romano E, Torres-Saavedra PA, Calderón Cartagena HI, Voas RB, Ramírez A. Alcohol-related risk of driver fatalities in motor vehicle crashes: comparing data from 2007 and 2013-2014. J Stud Alcohol Drugs 2018; 79(4): 547-52.
[http://dx.doi.org/10.15288/jsad.2018.79.547] [PMID: 30079869]
[150]
Davis JK, Green JM. Caffeine and anaerobic performance: ergogenic value and mechanisms of action. Sports Med 2009; 39(10): 813-32.
[http://dx.doi.org/10.2165/11317770-000000000-00000] [PMID: 19757860]
[151]
Davis JM, Zhao Z, Stock HS, Mehl KA, Buggy J, Hand GA. Central nervous system effects of caffeine and adenosine on fatigue. Am J Physiol Regul Integr Comp Physiol 2003; 284(2): R399-404.
[http://dx.doi.org/10.1152/ajpregu.00386.2002] [PMID: 12399249]
[152]
Kondo T, Kondo Y, Orita Y, et al. Predictive factors for efficacy and safety of prophylactic theophylline for extubation in infants with apnea of prematurity. PLoS One 2016; 11(7): e0157198
[http://dx.doi.org/10.1371/journal.pone.0157198] [PMID: 27388444]
[153]
Awaad AS, Soliman GA, Al-Outhman MR, et al. The effect of four coffee types on normotensive rats and normal/hypertensive human volunteers. Phytother Res 2011; 25(6): 803-8.
[http://dx.doi.org/10.1002/ptr.3333] [PMID: 21086544]
[154]
Shinohara T, Park HW, Han S, et al. Ca2+ clock malfunction in a canine model of pacing-induced heart failure. Am J Physiol Heart Circ Physiol 2010; 299(6): H1805-11.
[http://dx.doi.org/10.1152/ajpheart.00723.2010] [PMID: 20889842]
[155]
Deakins KM. Bronchopulmonary dysplasia. Respir Care 2009; 54(9): 1252-62.
[PMID: 19712501]
[156]
Duffy P, Phillips YY. Caffeine consumption decreases the response to bronchoprovocation challenge with dry gas hyperventilation. Chest 1991; 99(6): 1374-7.
[http://dx.doi.org/10.1378/chest.99.6.1374] [PMID: 2036818]
[157]
Goto A, Song Y, Chen BH, Manson JE, Buring JE, Liu S. Coffee and caffeine consumption in relation to sex hormone-binding globulin and risk of type 2 diabetes in postmenopausal women. Diabetes 2011; 60(1): 269-75.
[http://dx.doi.org/10.2337/db10-1193] [PMID: 21030499]
[158]
Paton CD, Lowe T, Irvine A. Caffeinated chewing gum increases repeated sprint performance and augments increases in testosterone in competitive cyclists. Eur J Appl Physiol 2010; 110(6): 1243-50.
[http://dx.doi.org/10.1007/s00421-010-1620-6] [PMID: 20737165]
[159]
Wendl B, Pfeiffer A, Pehl C, Schmidt T, Kaess H. Effect of decaffeination of coffee or tea on gastro-oesophageal reflux. Aliment Pharmacol Ther 1994; 8(3): 283-7.
[http://dx.doi.org/10.1111/j.1365-2036.1994.tb00289.x] [PMID: 7918922]
[160]
Jeppesen U, Loft S, Poulsen HE, Brśen K. A fluvoxamine-caffeine interaction study. Pharmacogenetics 1996; 6(3): 213-22.
[http://dx.doi.org/10.1097/00008571-199606000-00003] [PMID: 8807660]
[161]
Flanagan D. Understanding the grapefruit-drug interaction. Gen Dent 2005; 53(4): 282-5.
[PMID: 16158798]
[162]
Bressler R. Grapefruit juice and drug interactions. Exploring mechanisms of this interaction and potential toxicity for certain drugs. Geriatrics 2006; 61(11): 12-8.
[PMID: 17112309]
[163]
Cuciureanu M, Vlase L, Muntean D, Varlan I, Cuciureanu R. Grapefruit juice--drug interactions: Importance for pharmacotherapy. Rev Med Chir Soc Med Nat Iasi 2010; 114(3): 885-91.
[PMID: 21235125]
[164]
Genser D. Food and drug interaction: Consequences for the nutrition/health status. Ann Nutr Metab 2008; 52(Suppl. 1): 29-32.
[http://dx.doi.org/10.1159/000115345] [PMID: 18382075]
[165]
Hanley MJ, Cancalon P, Widmer WW, Greenblatt DJ. The effect of grapefruit juice on drug disposition. Expert Opin Drug Metab Toxicol 2011; 7(3): 267-86.
[http://dx.doi.org/10.1517/17425255.2011.553189] [PMID: 21254874]
[166]
Honda Y, Ushigome F, Koyabu N, et al. Effects of grapefruit juice and orange juice components on P-glycoprotein- and MRP2-mediated drug efflux. Br J Pharmacol 2004; 143(7): 856-64.
[http://dx.doi.org/10.1038/sj.bjp.0706008] [PMID: 15504753]
[167]
Konishi T, Satsu H, Hatsugai Y, et al. Inhibitory effect of a bitter melon extract on the P-glycoprotein activity in intestinal Caco-2 cells. Br J Pharmacol 2004; 143(3): 379-87.
[http://dx.doi.org/10.1038/sj.bjp.0705804] [PMID: 15351776]
[168]
Yoo HH, Lee M, Chung HJ, Lee SK, Kim DH. Effects of diosmin, a flavonoid glycoside in citrus fruits, on P-glycoprotein-mediated drug efflux in human intestinal Caco-2 cells. J Agric Food Chem 2007; 55(18): 7620-5.
[http://dx.doi.org/10.1021/jf070893f] [PMID: 17676865]
[169]
Satoh H, Yamashita F, Tsujimoto M, et al. Citrus juices inhibit the function of human organic anion-transporting polypeptide OATP-B. Drug Metab Dispos 2005; 33(4): 518-23.
[http://dx.doi.org/10.1124/dmd.104.002337] [PMID: 15640378]
[170]
Greenblatt DJ. Analysis of drug interactions involving fruit beverages and organic anion-transporting polypeptides. J Clin Pharmacol 2009; 49(12): 1403-7.
[http://dx.doi.org/10.1177/0091270009342251] [PMID: 19789373]
[171]
Sica DA. Interaction of grapefruit juice and calcium channel blockers. Am J Hypertens 2006; 19(7): 768-73.
[http://dx.doi.org/10.1016/j.amjhyper.2005.11.003] [PMID: 16814135]
[172]
Pawełczyk T, Kłoszewska I. [Grapefruit juice interactions with psychotropic drugs: Advantages and potential risk]. Przegl Lek 2008; 65(2): 92-5.
[PMID: 18663908]
[173]
Reamy BV, Stephens MB. The grapefruit-drug interaction debate: Role of statins. Am Fam Physician 2007; 76(2): 190-2.
[PMID: 17695563]
[174]
Paine MF, Widmer WW, Pusek SN, et al. Further characterization of a furanocoumarin-free grapefruit juice on drug disposition: Studies with cyclosporine. Am J Clin Nutr 2008; 87(4): 863-71.
[http://dx.doi.org/10.1093/ajcn/87.4.863] [PMID: 18400708]
[175]
Van den Bout-Van den Beukel CJ, Koopmans PP, van der Ven AJ, De Smet PA, Burger DM. Possible drug-metabolism interactions of medicinal herbs with antiretroviral agents. Drug Metab Rev 2006; 38: 477-514.
[http://dx.doi.org/10.1080/03602530600754065]
[176]
Bailey DG, Dresser GK. Interactions between grapefruit juice and cardiovascular drugs. Am J Cardiovasc Drugs 2004; 4(5): 281-97.
[http://dx.doi.org/10.2165/00129784-200404050-00002] [PMID: 15449971]
[177]
Dresser GK, Kim RB, Bailey DG. Effect of grapefruit juice volume on the reduction of fexofenadine bioavailability: Possible role of organic anion transporting polypeptides. Clin Pharmacol Ther 2005; 77(3): 170-7.
[http://dx.doi.org/10.1016/j.clpt.2004.10.005] [PMID: 15735611]
[178]
Libersa CC, Brique SA, Motte KB, et al. Dramatic inhibition of amiodarone metabolism induced by grapefruit juice. Br J Clin Pharmacol 2000; 49(4): 373-8.
[http://dx.doi.org/10.1046/j.1365-2125.2000.00163.x] [PMID: 10759694]
[179]
Amory JK, Amory DW Sr. Oral erythromycin and the risk of sudden death. N Engl J Med 2005; 352(3): 301-4.
[http://dx.doi.org/10.1056/NEJM200501203520317] [PMID: 15669119]
[180]
Stump AL, Mayo T, Blum A. Management of grapefruit-drug interactions. Am Fam Physician 2006; 74(4): 605-8.
[PMID: 16939181]
[181]
Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A. Interaction between grapefruit juice and diazepam in humans. Eur J Drug Metab Pharmacokinet 1998; 23(1): 55-9.
[http://dx.doi.org/10.1007/BF03189827] [PMID: 9625273]
[182]
Malhotra S, Bailey DG, Paine MF, Watkins PB. Seville orange juice-felodipine interaction: comparison with dilute grapefruit juice and involvement of furocoumarins. Clin Pharmacol Ther 2001; 69(1): 14-23.
[http://dx.doi.org/10.1067/mcp.2001.113185] [PMID: 11180034]
[183]
Kamath AV, Yao M, Zhang Y, Chong S. Effect of fruit juices on the oral bioavailability of fexofenadine in rats. J Pharm Sci 2005; 94(2): 233-9.
[http://dx.doi.org/10.1002/jps.20231] [PMID: 15570603]
[184]
Ho PC, Saville DJ, Coville PF, Wanwimolruk S. Content of CYP3A4 inhibitors, naringin, naringenin and bergapten in grapefruit and grapefruit juice products. Pharm Acta Helv 2000; 74(4): 379-85.
[http://dx.doi.org/10.1016/S0031-6865(99)00062-X] [PMID: 10812937]
[185]
Farkas D, Greenblatt DJ. Influence of fruit juices on drug disposition: discrepancies between in vitro and clinical studies. Expert Opin Drug Metab Toxicol 2008; 4(4): 381-93.
[http://dx.doi.org/10.1517/17425255.4.4.381] [PMID: 18433343]
[186]
Dresser GK, Bailey DG, Leake BF, et al. Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine. Clin Pharmacol Ther 2002; 71(1): 11-20.
[http://dx.doi.org/10.1067/mcp.2002.121152] [PMID: 11823753]
[187]
Rossi R, Porta S, Canovi B. Overview on cranberry and urinary tract infections in females. J Clin Gastroenterol 2010; 44(Suppl. 1): S61-2.
[http://dx.doi.org/10.1097/MCG.0b013e3181d2dc8e] [PMID: 20495471]
[188]
Izzo AA. Herb-drug interactions: An overview of the clinical evidence. Fundam Clin Pharmacol 2005; 19(1): 1-16.
[http://dx.doi.org/10.1111/j.1472-8206.2004.00301.x] [PMID: 15660956]
[189]
Pham DQ, Pham AQ. Interaction potential between cranberry juice and warfarin. Am J Health Syst Pharm 2007; 64(5): 490-4.
[http://dx.doi.org/10.2146/ajhp060370] [PMID: 17322161]
[190]
Li Y, Guo C, Yang J, Wei J, Xu J, Cheng S. Evaluation of antioxidant properties of pomegranate peel extract in comparison with pomegranate pulp extract. Food Chem 2006; 96(2): 254-60.
[http://dx.doi.org/10.1016/j.foodchem.2005.02.033]
[191]
Viuda-Martos M, Fernandez-Lopez J. Pomegranate and its many functional components as related to human health: A review, comprehensive review. 2010; 9(6): 635-54.
[192]
Hidaka M, Okumura M, Fujita K, et al. Effects of pomegranate juice on human cytochrome p450 3A (CYP3A) and carbamazepine pharmacokinetics in rats. Drug Metab Dispos 2005; 33(5): 644-8.
[http://dx.doi.org/10.1124/dmd.104.002824] [PMID: 15673597]
[193]
Nagata M, Hidaka M, Sekiya H, et al. Effects of pomegranate juice on human cytochrome P450 2C9 and tolbutamide pharmacokinetics in rats. Drug Metab Dispos 2007; 35(2): 302-5.
[http://dx.doi.org/10.1124/dmd.106.011718] [PMID: 17132763]
[194]
Saruwatari A, Okamura S, Nakajima Y, Narukawa Y, Takeda T, Tamura H. Pomegranate juice inhibits sulfoconjugation in Caco-2 human colon carcinoma cells. J Med Food 2008; 11(4): 623-8.
[http://dx.doi.org/10.1089/jmf.2007.0050] [PMID: 19053852]
[195]
Rivera-Pastrana DM, Yahia EM, González-Aguilar GA. Phenolic and carotenoid profiles of papaya fruit (Carica papaya L.) and their contents under low temperature storage. J Sci Food Agric 2010; 90(14): 2358-65.
[http://dx.doi.org/10.1002/jsfa.4092] [PMID: 20632382]
[196]
Rossetto MR, Oliveira do Nascimento JR, Purgatto E, Fabi JP, Lajolo FM, Cordenunsi BR. Benzylglucosinolate, benzylisothiocyanate, and myrosinase activity in papaya fruit during development and ripening. J Agric Food Chem 2008; 56(20): 9592-9.
[http://dx.doi.org/10.1021/jf801934x] [PMID: 18826320]
[197]
Seigler DS, Pauli GF, Nahrstedt A, Leen R. Cyanogenic allosides and glucosides from Passiflora edulis and Carica papaya. Phytochemistry 2002; 60(8): 873-82.
[http://dx.doi.org/10.1016/S0031-9422(02)00170-X] [PMID: 12150815]
[198]
Adeneye AA, Olagunju IA. Preliminary hypoglycemic and hypolipidemic activities of the aqueous seed extract of Carica papaya Linn. in Wistar rats. Biol Med (Aligarh) 2009; 1: 1-10.
[199]
Chávez-Quintal P, González-Flores T, Rodríguez-Buenfil I, Gallegos-Tintoré S. Antifungal activity in ethanolic extracts of Carica papaya L. cv. maradol leaves and seeds. Indian J Microbiol 2011; 51(1): 54-60.
[http://dx.doi.org/10.1007/s12088-011-0086-5] [PMID: 22282629]
[200]
Hidaka M, Fujita K, Ogikubo T, et al. Potent inhibition by star fruit of human cytochrome P450 3A (CYP3A) activity. Drug Metab Dispos 2004; 32(6): 581-3.
[http://dx.doi.org/10.1124/dmd.32.6.581] [PMID: 15155547]
[201]
Ribeiro FA, Gomes de Moura CF, Aguiar O Jr, et al. The chemopreventive activity of apple against carcinogenesis: antioxidant activity and cell cycle control. Eur J Cancer Prev 2014; 23(5): 477-80.
[http://dx.doi.org/10.1097/CEJ.0000000000000005] [PMID: 24366437]
[202]
Gerhauser C. Cancer chemopreventive potential of apples, apple juice, and apple components. Planta Med 2008; 74(13): 1608-24.
[http://dx.doi.org/10.1055/s-0028-1088300] [PMID: 18855307]
[203]
Pohl C, Will F, Dietrich H, Schrenk D. Cytochrome P450 1A1 expression and activity in Caco-2 cells: modulation by apple juice extract and certain apple polyphenols. J Agric Food Chem 2006; 54(26): 10262-8.
[http://dx.doi.org/10.1021/jf061791c] [PMID: 17177569]
[204]
Zafra-Stone S, Yasmin T, Bagchi M, Chatterjee A, Vinson JA, Bagchi D. Berry anthocyanins as novel antioxidants in human health and disease prevention. Mol Nutr Food Res 2007; 51(6): 675-83.
[http://dx.doi.org/10.1002/mnfr.200700002] [PMID: 17533652]
[205]
Del Rio D, Borges G, Crozier A. Berry flavonoids and phenolics: bioavailability and evidence of protective effects. Br J Nutr 2010; 104(Suppl. 3): S67-90.
[http://dx.doi.org/10.1017/S0007114510003958] [PMID: 20955651]
[206]
Juranić Z, Zizak Z. Biological activities of berries: From antioxidant capacity to anti-cancer effects. Biofactors 2005; 23(4): 207-11.
[http://dx.doi.org/10.1002/biof.5520230405] [PMID: 16498207]
[207]
Seeram NP, Adams LS, Zhang Y, et al. Blackberry, black raspberry, blueberry, cranberry, red raspberry, and strawberry extracts inhibit growth and stimulate apoptosis of human cancer cells in vitro. J Agric Food Chem 2006; 54(25): 9329-39.
[http://dx.doi.org/10.1021/jf061750g] [PMID: 17147415]
[208]
de Wet H, Nkwanyana MN, van Vuuren SF. Medicinal plants used for the treatment of diarrhoea in northern Maputaland, KwaZulu-Natal Province, South Africa. J Ethnopharmacol 2010; 130(2): 284-9.
[http://dx.doi.org/10.1016/j.jep.2010.05.004] [PMID: 20452415]
[209]
Junyaprasert VB, Soonthornchareonnon N, Thongpraditchote S, Murakami T, Takano M. Inhibitory effect of Thai plant extracts on P-glycoprotein mediated efflux. Phytother Res 2006; 20(1): 79-81.
[http://dx.doi.org/10.1002/ptr.1785] [PMID: 16397849]
[210]
Berardini N, Fezer R, Conrad J, Beifuss U, Carle R, Schieber A. Screening of mango (Mangifera indica L.) cultivars for their contents of flavonol O- and xanthone C-glycosides, anthocyanins, and pectin. J Agric Food Chem 2005; 53(5): 1563-70.
[http://dx.doi.org/10.1021/jf0484069] [PMID: 15740041]
[211]
Engels C, Knödler M, Zhao YY, Carle R, Gänzle MG, Schieber A. Antimicrobial activity of gallotannins isolated from mango (Mangifera indica L.) kernels. J Agric Food Chem 2009; 57(17): 7712-8.
[http://dx.doi.org/10.1021/jf901621m] [PMID: 19655802]
[212]
Bischoff SC. Quercetin: Potentials in the prevention and therapy of disease. Curr Opin Clin Nutr Metab Care 2008; 11(6): 733-40.
[http://dx.doi.org/10.1097/MCO.0b013e32831394b8] [PMID: 18827577]
[213]
Rodeiro I, Donato MT, Lahoz A, Garrido G, Delgado R, Gómez-Lechón MJ. Interactions of polyphenols with the P450 system: Possible implications on human therapeutics. Mini Rev Med Chem 2008; 8(2): 97-106.
[http://dx.doi.org/10.2174/138955708783498131] [PMID: 18289092]
[214]
Rodríguez-Fragoso L, Martínez-Arismendi JL, Orozco-Bustos D, Reyes-Esparza J, Torres E, Burchiel SW. Potential risks resulting from fruit/vegetable-drug interactions: Effects on drug-metabolizing enzymes and drug transporters. J Food Sci 2011; 76(4): R112-24.
[http://dx.doi.org/10.1111/j.1750-3841.2011.02155.x] [PMID: 22417366]
[215]
Halliwell B. Dietary polyphenols: good, bad, or indifferent for your health? Cardiovasc Res 2007; 73(2): 341-7.
[http://dx.doi.org/10.1016/j.cardiores.2006.10.004] [PMID: 17141749]
[216]
Skibola CF, Smith MT. Potential health impacts of excessive flavonoid intake. Free Radic Biol Med 2000; 29(3-4): 375-83.
[http://dx.doi.org/10.1016/S0891-5849(00)00304-X] [PMID: 11035267]
[217]
Galati G, O’Brien PJ. Potential toxicity of flavonoids and other dietary phenolics: significance for their chemopreventive and anticancer properties. Free Radic Biol Med 2004; 37(3): 287-303.
[http://dx.doi.org/10.1016/j.freeradbiomed.2004.04.034] [PMID: 15223063]
[218]
Velasco P, Francisco M, Moreno DA, Ferreres F, García-Viguera C, Cartea ME. Phytochemical fingerprinting of vegetable Brassica oleracea and Brassica napus by simultaneous identification of glucosinolates and phenolics. Phytochem Anal 2011; 22(2): 144-52.
[http://dx.doi.org/10.1002/pca.1259] [PMID: 21259374]
[219]
Anwar-Mohamed A, El-Kadi AO. Sulforaphane induces CYP1A1 mRNA, protein, and catalytic activity levels via an AhR-dependent pathway in murine hepatoma Hepa 1c1c7 and human HepG2 cells. Cancer Lett 2009; 275(1): 93-101.
[http://dx.doi.org/10.1016/j.canlet.2008.10.003] [PMID: 19013013]
[220]
Fimognari C, Lenzi M, Hrelia P. Interaction of the isothiocyanate sulforaphane with drug disposition and metabolism: Pharmacological and toxicological implications. Curr Drug Metab 2008; 9(7): 668-78.
[http://dx.doi.org/10.2174/138920008785821675] [PMID: 18781917]
[221]
Lhoste EF, Gloux K, De Waziers I, et al. The activities of several detoxication enzymes are differentially induced by juices of garden cress, water cress and mustard in human HepG2 cells. Chem Biol Interact 2004; 150(3): 211-9.
[http://dx.doi.org/10.1016/j.cbi.2004.08.007] [PMID: 15560888]
[222]
Lomnitski L, Bergman M, Nyska A, Ben-Shaul V, Grossman S. Composition, efficacy, and safety of spinach extracts. Nutr Cancer 2003; 46(2): 222-31.
[http://dx.doi.org/10.1207/S15327914NC4602_16] [PMID: 14690799]
[223]
Waliszewski KN, Blasco G. Nutraceutical properties of lycopene. Salud Publica Mex 2010; 52(3): 254-65.
[http://dx.doi.org/10.1590/S0036-36342010000300010] [PMID: 20485889]
[224]
Sikora M, Hallmann E, Rembiałkowska E. [The content of bioactive compounds in carrots from organic and conventional production in the context of health prevention]. Rocz Panstw Zakl Hig 2009; 60(3): 217-20.
[PMID: 20063690]
[225]
Sun T, Simon PW, Tanumihardjo SA. Antioxidant phytochemicals and antioxidant capacity of biofortified carrots (Daucus carota L.) of various colors. J Agric Food Chem 2009; 57(10): 4142-7.
[http://dx.doi.org/10.1021/jf9001044] [PMID: 19358535]
[226]
Blickstein D, Shaklai M, Inbal A. Warfarin antagonism by avocado. Lancet 1991; 337(8746): 914-5.
[http://dx.doi.org/10.1016/0140-6736(91)90244-J] [PMID: 1672990]
[227]
Vranckx P, Valgimigli M, Heidbuchel H. The Significance of drug-drug and drug-food interactions of oral anticoagulation. Arrhythm Electrophysiol Rev 2018; 7(1): 55-61.
[http://dx.doi.org/10.15420/aer.2017.50.1] [PMID: 29636974]
[228]
Bouraoui A, Brazier JL, Zouaghi H, Rousseau M. Theophylline pharmacokinetics and metabolism in rabbits following single and repeated administration of Capsicum fruit. Eur J Drug Metab Pharmacokinet 1995; 20(3): 173-8.
[http://dx.doi.org/10.1007/BF03189666] [PMID: 8751037]
[229]
Tian Q, Rosselot RA, Schwartz SJ. Quantitative determination of intact glucosinolates in broccoli, broccoli sprouts, Brussels sprouts, and cauliflower by high-performance liquid chromatography-electrospray ionization-tandem mass spectrometry. Anal Biochem 2005; 343(1): 93-9.
[http://dx.doi.org/10.1016/j.ab.2005.04.045] [PMID: 15963940]
[230]
Lampe JW, King IB, Li S, et al. Brassica vegetables increase and apiaceous vegetables decrease cytochrome P450 1A2 activity in humans: Changes in caffeine metabolite ratios in response to controlled vegetable diets. Carcinogenesis 2000; 21(6): 1157-62.
[http://dx.doi.org/10.1093/carcin/21.6.1157] [PMID: 10837004]
[231]
Lambert JD, Sang S, Lu AY, Yang CS. Metabolism of dietary polyphenols and possible interactions with drugs. Curr Drug Metab 2007; 8(5): 499-507.
[http://dx.doi.org/10.2174/138920007780866870] [PMID: 17584021]
[232]
Flockhart DA. Dietary restrictions and drug interactions with monoamine oxidase inhibitors: An update. J Clin Psychiatry 2012; 73(Suppl. 1): 17-24.
[http://dx.doi.org/10.4088/JCP.11096su1c.03] [PMID: 22951238]
[233]
Ismail MYM. Drug-food interactions and role of pharmacist. Asian J Phar Clin Res 2009; 2(4): 1-10.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 15
ISSUE: 1
Year: 2020
Page: [12 - 27]
Pages: 16
DOI: 10.2174/1574885514666190126141424
Price: $65

Article Metrics

PDF: 31
HTML: 5